Codexis (NASDAQ:CDXS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Codexis (NASDAQ:CDXS – Free Report) from a sell rating to a hold rating in a report issued on Saturday,Wall Street Zen reports.

A number of other brokerages also recently commented on CDXS. Weiss Ratings upgraded Codexis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 23rd. Benchmark reiterated a “hold” rating on shares of Codexis in a report on Thursday, August 20th. Finally, Piper Sandler dropped their target price on shares of Codexis from $9.00 to $8.00 and set an “overweight” rating for the company in a report on Monday, August 17th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Codexis has a consensus rating of “Hold” and a consensus price target of $6.00.

View Our Latest Report on CDXS

Codexis Stock Down 8.6%

Shares of CDXS opened at $1.06 on Friday. The firm has a market capitalization of $116.08 million, a P/E ratio of -5.30 and a beta of 2.38. Codexis has a 12-month low of $0.90 and a 12-month high of $2.98. The firm has a fifty day moving average price of $1.28 and a 200-day moving average price of $1.78. The company has a current ratio of 3.06, a quick ratio of 2.99 and a debt-to-equity ratio of 1.03.

Codexis (NASDAQ:CDXS – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.02. The company had revenue of $19.26 million during the quarter, compared to analyst estimates of $18.72 million. Codexis had a negative net margin of 21.77% and a negative return on equity of 45.54%. Equities research analysts expect that Codexis will post -0.37 earnings per share for the current year.

Institutional Trading of Codexis

A number of institutional investors and hedge funds have recently bought and sold shares of CDXS. BlackRock Inc. purchased a new stake in Codexis during the 2nd quarter worth about $16,463,000. Aberdeen Group plc increased its holdings in shares of Codexis by 59.5% in the 3rd quarter. Aberdeen Group plc now owns 10,797,702 shares of the biotechnology company’s stock valued at $15,009,000 after acquiring an additional 4,027,748 shares during the period. Nantahala Capital Management LLC acquired a new stake in shares of Codexis during the second quarter worth about $8,189,365. Private Advisor Group LLC purchased a new position in shares of Codexis in the 3rd quarter valued at approximately $1,677,000. Finally, Man Group plc purchased a new position in Codexis during the 2nd quarter worth $1,278,000. 78.54% of the stock is currently owned by hedge funds and other institutional investors.

About Codexis

(Get Free Report)

Codexis, Inc. is a biotechnology company that develops engineered enzymes for pharmaceutical and other manufacturing applications. Founded in 2002 and based in Redwood City, California, the company uses its protein-engineering platform, CodeEvolver, to design enzymes with properties suited to specific production processes. Codexis supplies enzymes and related development services for the manufacture of small-molecule drugs and other products. It also develops its ECO Synthesis platform, which uses enzymes to support the production of oligonucleotide therapeutics, including RNA-based medicines.

Featured Articles

Analyst Recommendations for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.